Cargando…
Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
Multiple myeloma (MM) is a largely incurable haematological malignancy defined by the clonal proliferation of malignant plasma cells (PCs) within the bone marrow. Clonal heterogeneity has recently been established as a feature in MM, however, the subclonal evolution associated with disease progressi...
Autores principales: | Dutta, Ankit K., Fink, J. Lynn, Grady, John P., Morgan, Gareth J., Mullighan, Charles G., To, Luen B., Hewett, Duncan R., Zannettino, Andrew C. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365384/ https://www.ncbi.nlm.nih.gov/pubmed/30046162 http://dx.doi.org/10.1038/s41375-018-0206-x |
Ejemplares similares
-
Using genomics to better define high-risk MGUS/SMM patients
por: Dutta, Ankit K., et al.
Publicado: (2018) -
Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
por: Konishi, Yoshinobu, et al.
Publicado: (2022) -
Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017) -
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020) -
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022)